Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells

Abstract excerpt

// Kyungsoo Ha 1 , Warren Fiskus 2,* , Dong Soon Choi 2,* , Srividya Bhaskara 3 , Leandro Cerchietti 4 , Santhana G. T. Devaraj 2 , Bhavin Shah 2 , Sunil Sharma 3 , Jenny C. Chang 2 , Ari M. Melnick 4 , Scott Hiebert 5 and Kapil N. Bhalla 2 1 Georgia Regents University, Augusta, GA 2 Houston Methodist Research Institute, Houston, TX 3 Huntsman Cancer Institute, Salt Lake City, UT 4 Weill Cornell Medical College,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CRISPR and Genetic Engineering
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy